Inventor
BOUTTON CARLO
BE37 patents
⚠️ This page may combine multiple inventors who share the name “BOUTTON CARLO”. Patents are grouped by organization below to help distinguish them — per-person disambiguation is on the roadmap.
ABLYNX NV
23 patentsUS11485777B2Nov 1, 2022
Immunoglobulin variable domains
ABLYNX NV8 citations94
US11312765B2Apr 26, 2022
Immunoglobulin variable domains
ABLYNX NV9 citations94
US11312764B2Apr 26, 2022
Immunoglobulin variable domains
ABLYNX NV10 citations94
US11220539B2Jan 11, 2022
Immunoglobulin variable domains
ABLYNX NV9 citations94
US10858418B2Dec 8, 2020
Techniques for predicting, detecting and reducing aspecific protein interference in assays involving immunoglobulin single variable domains
ABLYNX NV18 citations93
US11708404B2Jul 25, 2023
Immunoglobulin variable domains
ABLYNX NV4 citations86
US11485778B2Nov 1, 2022
Immunoglobulin variable domains
ABLYNX NV7 citations86
US11319364B2May 3, 2022
Immunoglobulin variable domains
ABLYNX NV8 citations86
US11426468B2Aug 30, 2022
Cysteine linked nanobody dimers
ABLYNX NV14 citations83
US11192937B2Dec 7, 2021
Techniques for predicting, detecting and reducing aspecific protein interference in assays involving immunoglobulin single variable domains
ABLYNX NV5 citations83
US11192938B2Dec 7, 2021
Serum albumin binding proteins containing immunoglobulin single variable domains
ABLYNX NV5 citations83
US9969805B2May 15, 2018
Amino acid sequences directed against HER2 and polypeptides comprising the same for the treatment of cancers and/or tumors
ABLYNX NV10 citations83
US12516105B2Jan 6, 2026
Techniques for predicting, detecting and reducing aspecific protein interference in assays involving immunoglobulin single variable domains
ABLYNX NV1 citations74
US12180268B2Dec 31, 2024
Immunoglobulin variable domains
ABLYNX NV2 citations73
US11306139B2Apr 19, 2022
Glycosylated immunoglobulin single variable domains
ABLYNX NV2 citations73
US12006352B2Jun 11, 2024
Techniques for predicting, detecting and reducing aspecific protein interference in assays involving immunoglobulin single variable domains
ABLYNX NV1 citations72
US11644471B2May 9, 2023
Techniques for predicting, detecting and reducing aspecific protein interference in assays involving immunoglobulin single variable domains
ABLYNX NV2 citations72
US11021544B2Jun 1, 2021
Nanobody dimers linked via C-terminally engineered cysteins
ABLYNX NV4 citations71
US11932702B2Mar 19, 2024
Polypeptides comprising immunoglobulin single variable domains targeting glypican-3 and T cell receptor
ABLYNX NV3 citations64
USRE50682EDec 2, 2025
Immunoglobulin variable domains
ABLYNX NV0 citations63
US11466089B2Oct 11, 2022
Chemokine receptor binding polypeptides
ABLYNX NV0 citations61
US12384835B2Aug 12, 2025
Cysteine linked nanobody dimers
ABLYNX NV0 citations60
US12480957B2Nov 25, 2025
Method of screening for anti-drug antibodies against immunoglobulin single variable domain-based drugs
ABLYNX NV0 citations47
MERCK SHARP & DOHME
6 patentsUS10544222B2Jan 28, 2020
PD1/CTLA4 binders
MERCK SHARP & DOHME22 citations93
US10501542B2Dec 10, 2019
CTLA4 binders
MERCK SHARP & DOHME16 citations93
US10323090B2Jun 18, 2019
PD1 and/or LAG3 binders
MERCK SHARP & DOHME26 citations93
US11155619B2Oct 26, 2021
PD1 and/or LAG3 binders
MERCK SHARP & DOHME4 citations83
US11168136B2Nov 9, 2021
PD1 and/or LAG3 binders
MERCK SHARP & DOHME2 citations72
US11168135B2Nov 9, 2021
PD1 and/or LAG3 binders
MERCK SHARP & DOHME2 citations72
REVETS HILDE ADI PIERRETTE
2 patentsUS8975382B2Mar 10, 2015
Amino acid sequences directed against HER2 and polypeptides comprising the same for the treatment of cancers and/or tumors
REVETS HILDE ADI PIERRETTE42 citations95
US8217140B2Jul 10, 2012
Peptides capable of binding to serum proteins and compounds, constructs and polypeptides comprising the same
REVETS HILDE ADI PIERRETTE11 citations82